What BMI do you need for weight loss medication?

You're probably here because you want a straight answer: does your BMI qualify you for weight loss medication? If you’re at the point of checking your eligibility, you’re in the right place. Here's how it works in the UK.

How weight loss medication is prescribed in the UK

In the UK, weight loss medications like Wegovy (semaglutide) and Mounjaro (tirzepatide) are licensed by the medicines regulator (MHRA) and prescribed based on clinical thresholds set by NICE.¹,²

Eligibility for these medications is a clinical decision. A UK-registered clinician will look at your BMI alongside your wider health and weight history. A high BMI doesn't guarantee a prescription. If your BMI sits on the borderline between categories, you might still meet the criteria if you have a weight-related condition.

Common BMI thresholds used in weight loss prescribing

There are two BMI thresholds for prescription weight loss medication in the UK, and which one applies depends on your wider health.²,³

The standard threshold (BMI ≥ 30)

For most adults, treatment can be considered when BMI sits at 30 or above, which is the range clinically classified as obese.⁴ At this level, weight is linked to a higher risk of cardiovascular disease, type 2 diabetes, and other chronic conditions, so support through weight loss treatment may be appropriate alongside diet and activity changes.⁵

The comorbidity threshold (BMI ≥ 27)

Treatment may also be considered at a lower BMI of 27 or above if you already experience a weight-related health condition.²,³ This is because if you have a BMI of 27 with a comorbidity, your medical risk profile is often comparable to, or higher than, if you had a BMI of 30 without one.⁶

Common weight-related conditions include:

• Type 2 diabetes

• High blood pressure (hypertension)

• Obstructive sleep apnoea

• Dyslipidaemia (raised cholesterol or triglycerides)

• Cardiovascular disease

Ethnicity-specific thresholds

For adults from Black, South Asian, Chinese, Middle Eastern, and other minority ethnic backgrounds, NICE recommends lower BMI cut-offs, typically reduced by around 2.5 points.²,⁷ This is because these groups tend to develop weight-related metabolic risk, particularly type 2 diabetes, at lower BMI values than White European populations.⁷

These figures guide clinical decisions, but they aren't the whole picture. Your prescriber will weigh them against your full health profile before recommending treatment.

Key facts: medication eligibility

• The standard BMI requirement for weight loss medication in the UK is 30 or above.²,³

• A BMI of 27 or above may qualify - depending on clinical assessment and medical history - if you have a weight-related condition such as type 2 diabetes or hypertension.²,³

• BMI thresholds are typically lowered by around 2.5 points for adults of Black, South Asian, Chinese, or Middle Eastern heritage.⁷

• A clinical assessment by a UK-registered prescriber is mandatory for every weight loss prescription.⁸

• Weight loss medication works best when used alongside a reduced-calorie diet, more physical activity, and behavioural support.⁹,¹⁰

The clinical assessment process

Why BMI is only the start

BMI is a screening tool rather than a diagnosis, and it doesn't measure body composition, fat distribution, or metabolic health on its own.¹,¹¹ A full clinical assessment is needed to confirm whether treatment is suitable, safe, and likely to help, so your clinician will also review your medical history, current medications, and any conditions that could affect treatment.⁸

The Numan online consultation

Numan's process begins with an online consultation, where you'll answer a series of clinical questions covering your health history, lifestyle, existing health conditions, and goals. You'll also share your measurements so that a clinician can verify your BMI against the relevant threshold.

Clinician oversight

Every Numan Weight Loss Programme is reviewed and managed by the clinical team, who will decide whether medical treatment is appropriate for you. If treatment isn't the right fit, your clinician will explain why, and may suggest alternative routes for managing your weight.

This thorough approach is there for good reason. GLP-1 receptor agonists are evidence-based treatments that are most effective when matched with the appropriate patient and managed alongside lifestyle support.⁸,⁹

BMI for weight loss medication: your questions answered

Can I be prescribed medication if my BMI is 26?

In most cases, no. UK guidance doesn't generally support prescribing weight loss medication below a BMI of 27, even when a weight-related condition is present.²,³ If you sit just below the threshold, your clinician may discuss other options, including lifestyle support, structured weight management programmes, and reassessment if your BMI moves into an eligible range.

Does muscle mass affect my eligibility?

BMI does not separate fat mass from lean muscle, so highly muscular adults can register a high BMI without carrying excess body fat.¹,¹¹,¹² Clinicians know this, and they will look at your full clinical picture before determining whether weight loss medication is right for you. For the majority of adults, however, BMI remains a reliable indicator of weight-related health risk.⁵

Are these treatments available for women?

Yes. GLP-1 receptor agonists licensed for weight management in the UK are available to both women and men who meet the clinical criteria,³ and Numan's weight loss service is open to adults who meet the eligibility criteria regardless of sex.

Next steps: check your eligibility

If you're unsure of what range you currently sit in, use our BMI calculator before starting your consultation to find your score. To learn more about why losing excess weight matters clinically, read our guide to the health risks of a high BMI.

The numan take

Although it doesn't tell you everything about your health, knowing your BMI score can give you an idea of whether you're eligible for weight loss medication. If you meet the criteria, weight loss treatment can be an effective clinical tool when used alongside the right lifestyle changes. But if you don't, there are still meaningful ways to protect and improve your long-term health. Knowing where you stand is the first step, and acting on it is the next.

References

1. Wu Y, Li D, Vermund SH. Advantages and limitations of the body mass index (BMI) to assess adult obesity. Int J Environ Res Public Health. 2024;21(6):757.

2. National Institute for Health and Care Excellence. Overweight and obesity management [NG246]. London: NICE; 2023.

3. National Institute for Health and Care Excellence. Semaglutide for managing overweight and obesity [TA875]. London: NICE; 2023.

4. Nuttall FQ. Body mass index: obesity, BMI, and health: a critical review. Nutr Today. 2015;50(3):117–128.

5. Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: a population-based cohort study of 3.6 million adults in the UK. Lancet Diabetes Endocrinol. 2018;6(12):944–953.

6. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715–725.

7. Caleyachetty R, Barber TM, Mohammed NI, Cappuccio FP, Hardy R, Mathur R, et al. Ethnicity-specific BMI cutoffs for obesity based on type 2 diabetes risk in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2021;9(7):419–426.

8. National Institute for Health and Care Excellence. Tirzepatide for managing overweight and obesity [TA1026]. London: NICE; 2024.

9. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.

10. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–217.

11. Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584–595.

12. Provencher MT, Chahla J, Sanchez G, Cinque ME, Kennedy NI, Whalen J, et al. Body mass index versus body fat percentage in prospective National Football League athletes: overestimation of obesity rate in athletes at the National Football League Scouting Combine. J Strength Cond Res. 2018;32(4):1013–1019.

13. Gonzalez MC, Correia MITD, Heymsfield SB. A requiem for BMI in the clinical setting. Curr Opin Clin Nutr Metab Care. 2017;20(5):314–321.